Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202621 | 1.00 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL951953 | 1.00 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL951954 | 1.00 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL2202617 | 1.00 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL917596 | 0.90 | NR1H2 (0.56) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL71583 | 0.90 | NR1H2 (0.56) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL72800 | 0.90 | NR1H2 (0.56) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL666524 | 0.90 | NR1H2 (0.56) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL25870404 | 0.89 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL23288691 | 0.89 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-11129832-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210139483-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2021-05-13 | — | — | US | disclosed |
| EP-3517536-B1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200188397-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| EP-3517536-A1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20190224190-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-25 | — | — | US | disclosed |
| US-10307414-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180370955-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2018-12-27 | — | — | US | disclosed |
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7868014-B2 | 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mGluR3 antagonists | ELI LILLY AND COMPANY (US) | 2011-01-11 | — | — | US | disclosed |
| US-7834021-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100203162-A1 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| EP-2182953-A2 | NEW PYRAZOL DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| EP-1805165-B1 | 1-(HETERO)ARYL-3-AMINO-PYRROLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20090247474-A1 | 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors | INCYTE CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013211-A2 | NEW PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | ELI LILLY AND COMPANY (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370955-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | NR1H2 2487/4885USP2 972/4885SMN1; SMN2 2291/4885 |
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | CDKL5, CDK15, CDK5 | NR1H2 3429/4885USP2 3715/4885SMN1; SMN2 3122/4885 |
| US-20100203162-A1 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | CYP7A1, MT-ND1, DNM1 | NR1H2 1541/4885USP2 4595/4885SMN1; SMN2 399/4885 |
| US-11129832-B2 | Biheteroaryl compounds and uses thereof | BCHE, SNCA, HAX1 | NR1H2 141/4885USP2 4746/4885SMN1; SMN2 51/4885 |
| US-20210139483-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES | IL5, THPO, TYMP | NR1H2 3395/4885USP2 4760/4885SMN1; SMN2 3058/4885 |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | NR1H2 2487/4885USP2 972/4885SMN1; SMN2 2291/4885 |
| US-20190224190-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | BTK, LCK, TYK2 | NR1H2 3502/4885USP2 3732/4885SMN1; SMN2 3923/4885 |
| US-20090247474-A1 | 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors | CCR2, CXCR3, CCR5 | NR1H2 170/4885USP2 4681/4885SMN1; SMN2 4846/4885 |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | NR1H2 228/4885USP2 3508/4885SMN1; SMN2 4368/4885 |
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | GRM3, GRM1, GRIA3 | NR1H2 590/4885USP2 4382/4885SMN1; SMN2 3608/4885 |
| US-20200188397-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, HAX1 | NR1H2 141/4885USP2 4746/4885SMN1; SMN2 51/4885 |
| US-10307414-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | BTK, LCK, TYK2 | NR1H2 3502/4885USP2 3732/4885SMN1; SMN2 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.